Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 2,635 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intermediate dose Clear all
Completed Phase 3 Interventional

Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass

NCT00587444
View directory record Official record
Conditions
Postoperative Hemorrhage
Interventions
Heparin, HH or high heparin, heparin concentration HC
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 29, 2026, 10:29 PM EDT
Active, not recruiting Phase 1 Interventional

High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

NCT01655836
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
Brachytherapy, Stereotactic Body Radiation Therapy, Quality-of-life assessment, Questionnaire administration
Radiation · Procedure · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2040
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 29, 2026, 10:29 PM EDT
Withdrawn Phase 2 Interventional

iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)

NCT03207334
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Midostaurin, Cytarabine
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 29, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants

NCT01888432
View directory record Official record
Conditions
Liver Transplantation
Interventions
Everolimus + reduced tacrolimus, Standard tacrolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 29, 2026, 10:29 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

SUV PDL1/PD1 in Sun Damaged & Sun Protected Human Skin of Participants

NCT06177106
View directory record Official record
Conditions
Other Skin Changes Due to Chronic Exposure to Nonionizing Radiation
Interventions
Solar Simulated Light
Other
Lead sponsor
University of Arizona
Other
Eligibility
40 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 29, 2026, 10:29 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

NCT03655444
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Abemaciclib, Nivolumab, Tumor biopsy, Peripheral blood, EORTC QLQ-30
Drug · Procedure · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 29, 2026, 10:29 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer

NCT06023277
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
ConvitVax
Biological
Lead sponsor
Jacinto Convit World Organization Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Pompano Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 29, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.

NCT00377637
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate mofetil (MMF), Cyclophosphamide, Azathioprine, Placebo to Azathioprine, Placebo to Mycophenolate mofetil, Corticosteroid
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 75 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
28
States / cities
Huntsville, Alabama • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 29, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Results available

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

NCT03273712
View directory record Official record
Conditions
Neuroendocrine Tumors, Meningioma, Neuroblastoma, Medulloblastoma
Interventions
90Y-DOTA tyr3-Octreotide, 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan, Amino Acids
Radiation · Diagnostic Test · Drug
Lead sponsor
University of Iowa
Other
Eligibility
6 Months to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 29, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients

NCT01792830
View directory record Official record
Conditions
Poor Glycemic Control
Interventions
Metformin, Glargine insulin, Glulisine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 29, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Results available

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

NCT01570036
View directory record Official record
Conditions
Breast Cancer
Interventions
Herceptin, NeuVax vaccine, GM-CSF
Drug
Lead sponsor
George E. Peoples
Industry
Eligibility
18 Years and older · Female only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
29
States / cities
Beverly Hills, California • Santa Monica, California • Santa Rosa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 29, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

NCT01209065
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
GSK1349572, Fosamprenavir, Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 29, 2026, 10:29 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Study of Allogeneic Human Dermal Fibroblasts for Remodeling Scar Contractures

NCT01564407
View directory record Official record
Conditions
Restrictive Scar Contracture, Restrictive Hypertrophic Scar, Burn Scar Contractures, Burn Scar
Interventions
ICX-RHY-013
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 29, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)

NCT02859129
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
rosuvastatin 40 mg tablet, Epanova™ QD (2 x 1 g capsules), Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose, Multiple (20) oral doses of 2 g Vascepa® every 12 hours
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 29, 2026, 10:29 PM EDT
Completed Not applicable Interventional Results available

Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients

NCT00574353
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 29, 2026, 10:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Biological Basis of Individual Variation in Social Cooperation

NCT01566539
View directory record Official record
Conditions
Healthy
Interventions
Intranasal Oxytocin (OT) 24 IU, Intranasal Vasopressin (AVP), Intranasal Placebo, Intranasal Vasopressin (AVP) 40 IU, Lorazepam
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 30 Years
Enrollment
707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 29, 2026, 10:29 PM EDT
Terminated Phase 1 Interventional Results available

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

NCT05061537
View directory record Official record
Conditions
Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer, Bladder Cancer, Sarcoma, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Squamous Cell Carcinoma
Interventions
PF-07263689, Sasanlimab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 29, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

NCT00529529
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
56
States / cities
Glendale, Arizona • Phoenix, Arizona • Encinitas, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2011 · Synced Oct 29, 2026, 10:29 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pharmacodynamics of Nasal and Buccal Midazolam Using EEG

NCT01316445
View directory record Official record
Conditions
Epilepsy
Interventions
nasal Midazolam
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Oct 29, 2026, 10:29 PM EDT
Active, not recruiting Early Phase 1 Interventional

LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma

NCT03684980
View directory record Official record
Conditions
Central Nervous System Lymphoma
Interventions
Methotrexate, Rituximab, leucovorin, Glucarpidase
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Boston, Massachusetts • Basking Ridge, New Jersey + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 29, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants

NCT05138653
View directory record Official record
Conditions
Healthy Participants
Interventions
CVL-354, Placebo
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 29, 2026, 10:29 PM EDT
Completed Not applicable Interventional Results available

Ultrasound-Assisted Paravertebral Block v. Traditional Paravertebral Block For Pain Control

NCT01949480
View directory record Official record
Conditions
Paravertebral Peripheral Nerve Block, Acute Pain Management
Interventions
Thoracotomy, Video-Assisted Thoracoscopic Surgery (VATS)
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 29, 2026, 10:29 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Lithium for Suicidal Behavior in Mood Disorders

NCT01928446
View directory record Official record
Conditions
Depressive Disorder, Bipolar Disorder, Suicide, Suicide, Attempted
Interventions
Lithium, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 29, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

Confirmatory Study Nepafenac 0.3%

NCT01109173
View directory record Official record
Conditions
Cataract
Interventions
Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Ophthalmic Suspension 0.3% Vehicle, NEVANAC Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
2,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2012 · Synced Oct 29, 2026, 10:29 PM EDT